Brief: Catalyst Biosciences Q3 Loss Per Share $0.80

Gyre Therapeutics

12/11/2021 12:41

Nov 12 (Reuters) - Catalyst Biosciences Inc  CBIO.O :
    * Q3 LOSS PER SHARE $0.80
    * COMPANY TO DISCONTINUE MARZAA DEVELOPMENT; FOCUS ON
DEVELOPING
ITS COMPLEMENT PORTFOLIO
    * ANNOUNCES CHANGE IN CORPORATE STRATEGY
    * EXPLORING OPPORTUNITIES TO LICENSE OR SELL OUR MARZAA AND
DALCA
(ENGINEERED FIX) PORTFOLIOS
    * HALTING DEVELOPMENT OF MARZAA WILL ALLOW US TO REDUCE OUR
BURN
RATE BY APPROXIMATELY 40%
    * CATALYST BIOSCIENCES - ENROLLMENT IN MARZAA CLINICAL
TRIALS
ADVERSELY IMPACTED BY SEVERAL FACTORS; NO LONGER FEASIBLE TO
DELIVER TOPLINE DATA IN 2022
    * WILL ADVANCE CLINICAL DEVELOPMENT OF CB 4332, AN SQ-DOSED
ENHANCED COMPLEMENT FACTOR I (CFI), AS SWIFTLY AS POSSIBLE

Source text for Eikon:  ID:nGNX5DshSL 
Further company coverage:  CBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))